Search Results for “cancer” – Page 32 – media

NICE recommends more genetic testing for links to ovarian cancer

Around 340,000 to 444,000 people in the UK carry one of nine pathogenic gene variants The National Institute for Health and Care Excellence (NICE) has recommended that more people get tested for genes linked to ovarian cancer. The new guideline aims to raise awareness and increase the availability of genetic testing, allowing people to take preventive measures, including surgery, to prevent the development of ovarian cancer. Anyone can carry a gene linked to ovarian cancer, including women, men, transgender people, and non-binary people, which can be passed on to their children. In the UK, around 340,000 to 440,000 people carry one of the nine pathogenic variants – BRCA1, BRCA2, MLH1, MSH2, MSH6, RAD51C, RAD51D, BRIP1 and PALB2 – that cause cancer, 3% of whom know they have a high-risk gene. NICE has recommended that genetic services should test and assess the likelihood of people carrying the genes, including those who ...
- Source: drugdu
- 101
- September 30, 2023
Novartis’ Lutathera Clears Phase III as Frontline Treatment for Rare Neuroendocrine Cancer

By Tristan Manalac Pictured: Novartis logo on its office in California/iStock, JHVEPhoto Novartis’ radioligand therapy Lutathera (lutetium Lu 177 dotatate) met its primary endpoint in the Phase III NETTER-2 trial in gastroenteropancreatic neuroendocrine tumors, the company announced Monday. NETTER-2 is a randomized and open-label trial that evaluated Lutathera as a first-line option in 222 patients with grade 2 or 3, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Only those whose cancers were positive for the somatostatin receptor (SSTR) were eligible for enrolment into NETTER-2. When used in combination with high-dose long-acting octreotide, Lutathera led to a significant improvement in progression-free survival (PFS)—the study’s primary endpoint—compared with octreotide alone. In terms of safety, NETTER-2 did not find any new signals of concern and Lutathera’s adverse event profile in the study was consistent with what had been previously established. Novartis did not provide specific efficacy and safety figures, though it promised to do so ...
- Source: drugdu
- 132
- September 28, 2023
kICR researchers develop new test to help identify future cancer treatments

Researchers from the Institute of Cancer Research’s (ICR) Centre for Cancer Drug Discovery have developed a new test, RKD2, which makes the early stages of drug discovery for cancer more efficient. Funded by Cancer Research UK, the researchers created an investigative procedure that can help scientists identify new biologically active compounds to be used to develop effective medications. Fragment-based drug discovery uses various techniques to screen libraries of compounds, or fragments, with a low molecular weight. During the initial stage, scientists introduce a potential anti-cancer target and see which fragments interact with it. Previously, researchers could only determine that ‘yes, an interaction occurred’ or ‘no, there was no interaction’. However, it was difficult to apply this to weak interactions, and the team could not rule out nonspecific interactions. The new RKD2 test allows researchers to quantify interactions by determining their strength, identifying those that are truly active and worth following ...
- Source: drugdu
- 141
- September 22, 2023
Novartis Returns Cancer Asset Tislelizumab to BeiGene

By Tristan Manalac Pictured: Novartis’ head office in Canada/iStock, JHVEPhoto Novartis on Tuesday gave back the investigational monoclonal antibody tislelizumab to BeiGene, returning worldwide rights to develop, manufacture and commercialize the anti-PD-1 candidate to the cancer-focused biotech. Also on Tuesday, BeiGene announced that the European Commission had approved tislelizumab for patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who had previously failed platinum-based chemotherapy. The treatment will be marketed under the brand name Tevimbra. After more than a year of regulatory delay, the FDA has also accepted BeiGene’s Biologics License Application (BLA) for tislelizumab as a first-line treatment option in this indication, according to Tuesday’s announcement. Novartis and BeiGene first entered into a collaboration and license agreement over tislelizumab in January 2021 to develop tislelizumab in ESCC, as well as other malignant diseases such as non-small cell lung cancer and hepatocellular carcinoma. In July 2022, however, ...
- Source: drugdu
- 113
- September 21, 2023
CancerVAX joins forces with UCLA to develop a universal CAR-T cell therapy

CancerVAX has announced the development of a universal chimeric antigen receptor (CAR) T-cell platform in partnership with a research team from the University of California, Los Angeles (UCLA). The company plans to adapt the nanoparticle technology developed by the UCLA team, which is currently being used for a universal cancer vaccine project to target T cells. The nanoparticle technology is inspired by the lipid nanoparticle and messenger RNA (mRNA) technology used to develop Covid-19 vaccines. Conventional CAR-T therapies rely on gene editing performed in the laboratory to transform the allogeneic T cells to induce CAR protein expression before reinfusion of these calls back into the patient. The universal CAR-T cell therapy would use injectable smart nanoparticles, which would be loaded with genetic information for specific cancer cell targeting. These nanoparticles would attach to the patient’s T cells and reprogram them to target specific cancer cells. CancerVAX has reported that preliminary ...
- Source: drugdu
- 148
- September 14, 2023
Seagen, Nurix Team to Create New Class of Antibody Conjugates for Cancer

By Tristan Manalac Pictured: Illustration of an antibody molecule/iStock, Dr_Microbe Seagen on Thursday inked a strategic collaboration agreement with San Francisco-based Nurix Therapeutics to develop a potentially new class of therapies—called degrader-antibody conjugates—that selectively kill cancer cells. Under the terms of the agreement, Seagen will make an upfront payment of $60 million and pledge up to $3.4 billion in research, development, regulatory and commercial milestone payments. Nurix will also be entitled to receive mid-single to low-double digit tiered royalties on future sales. The California biotech will also have the option for profit-sharing and co-promotion in the U.S., applicable to two products that emerge from the partnership. Seagen and Nurix will combine their respective expertise and produce degrader-antibody conjugates (DACs), which combine the “tissue and tumor specificity of antibodies with highly potent and catalytic targeted degradation of cancer driver proteins,” Nurix CEO Arthur Sands said in a statement. To achieve this, ...
- Source: drugdu
- 210
- September 12, 2023
ICR study finds way to determine efficacy of experimental breast cancer drugs

Researchers at The Institute of Cancer Research (ICR), London, have discovered a way to use a simple, non-invasive MRI scan to determine whether an experimental approach to enhance treatment for breast cancer is effective. New research from the study, funded by Cancer Research UK, could help doctors visualise tumours and speed up the development of targeted therapies for breast cancer. If successful, these drugs could enhance the effectiveness of other drugs administered in combination. Common features of breast cancer include excessive connective tissue, which consists of cells and fibres that provide a scaffold, known as the extracellular matrix (ECM), where tumours can grow. Hyaluronic acid, which works by absorbing water, is naturally present inside the tumour ECM and causes cancer tumours to swell, making it challenging for drugs to penetrate, reach and destroy cancer cells. Researchers are able to use experimental drugs that target and degrade a chemical called hyaluronic ...
- Source: drugdu
- 98
- September 12, 2023
Veracyte and Gustave Roussy announce partnership for cancer therapies

Veracyte has announced a multi-year partnership with Gustave Roussy to support biopharmaceutical companies in expediting the development of new cancer therapies. They will combine their abilities to offer new insights into the biology of metastatic tumours, helping to develop new cancer treatments. The collaboration will utilise Gustave Roussy’s extensive collection of tumour samples and related data, along with Veracyte’s Biopharma Atlas, a machine learning-powered, multi-omic solution aimed at enhancing the effectiveness and efficacy of clinical studies. Gustave Roussy’s department of therapeutic innovation and early clinical trials will deliver metastatic tumour samples and information for several cancer indications. These are derived from research projects, specifically for new immunotherapies. Veracyte intends to combine these resources with its multi-omics testing and machine learning capabilities, resulting in the development of a Veracyte Biopharma Atlas reference database for genomic and immunomic biomarkers. Using the comprehensive understanding of each tumour’s biology, especially its immune context, the ...
- Source: drugdu
- 141
- September 11, 2023
Guardant abandons cancer blood test trial early, restates confidence in product line

Dive Brief Guardant Health has stopped a trial of a minimum residual disease (MRD) test early after seeing the results of an interim analysis. The study, called COBRA, was evaluating the ability of Guardant’s MRD blood test to improve outcomes in patients with stage II colon cancer after surgery. Patients underwent circulating tumor deoxyribonucleic acid testing to inform further treatment. Guardant, which collaborated with NRG Oncology on the study, has yet to share data from the trial but confirmed it stopped early after the news leaked on social media. Shares in Guardant fell around 13% to below $35 on Friday. Dive Insight Guardant and NRG Oncology, a clinical trial group funded by the National Cancer Institute, began the trial in 2020 on the strength of evidence that the LUNAR-1 blood test may help identify patients who are likely to benefit from chemotherapy after surgery. The test, the product of a ...
- Source: drugdu
- 122
- September 8, 2023
Following in Tecentriq’s footsteps, Alecensa gives Roche another win in early-stage lung cancer

After a groundbreaking approval for Tecentriq, Roche has another positive early-stage lung cancer trial to celebrate. This time, the honor belongs to a targeted therapy in Alecensa. Alecensa, compared with chemotherapy, reduced the risk of tumor recurrence or death when used after surgery in certain non-small cell lung cancer patients, Roche said Friday. The patients had ALK-positive, stage 1b to 3a tumors that were completely resected before taking Alecensa. The positive readout, from the ALINA trial, makes Alecensa the first ALK inhibitor to show a benefit in early-stage NSCLC in a phase 3 trial, Roche noted. Data on patient survival remain immature. But the Swiss pharma said it’ll submit the results to the FDA and the European Medicines Agency for a potential label expansion. “If approved, Alecensa has the potential to treat cancer before it has spread in a setting where treatment can increase the chances of cure,” Roche’s chief ...
- Source: drugdu
- 113
- September 6, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.